Suppr超能文献

华法林在老年房颤患者治疗中是否未得到充分应用?

Is warfarin underused in the treatment of elderly persons with atrial fibrillation?

作者信息

Whittle J, Wickenheiser L, Venditti L N

机构信息

Department of Medicine, University of Pittsburgh, Pa, USA. JAYDUB+@PITT.EDU

出版信息

Arch Intern Med. 1997 Feb 24;157(4):441-5.

PMID:9046896
Abstract

BACKGROUND

Several randomized clinical trials have shown that among patients with atrial fibrillation, warfarin sodium use protects against stroke. Recently, experts have voiced concern about possible underuse of warfarin by practicing physicians. Few studies, however, have quantitated the amount of warfarin underuse.

METHODS

We randomly sampled 65 Medicare beneficiaries discharged alive from each of 5 small Pennsylvania hospitals between July 1, 1993, and June 30, 1994, with a discharge diagnosis code for atrial fibrillation. Trained abstractors verified that atrial fibrillation was present at some time during the hospitalization, determined the presence of contraindications to anticoagulation, and identified warfarin or aspirin use at discharge for each patient. An internist used implicit criteria to identify the reason for warfarin nonuse in patients who had none of the explicit contraindications to warfarin and did not receive it.

RESULTS

Of 322 charts reviewed, 48 patients were not in atrial fibrillation during the hospitalization, 79 had contraindications to warfarin use, 21 either died or were transferred to another hospital, and 2 were admitted with a complication of warfarin. Of the 172 remaining patients, 76 (44%) underwent anticoagulation. On implicit review of the 96 patients who did not undergo anticoagulation, the internist judged that warfarin would not have been appropriate in 54. After excluding those patients, 76 (64%) of the remaining 118 patients underwent anticoagulation. Patients not receiving warfarin were slightly older (81.6 vs 78.3 years old), but this was not statistically significant after stratifying by hospital. Rates of warfarin use at the 5 hospitals varied widely (32%, 57%, 79%, 82%, 94%; P < .001, chi2 with 4 df). Patients with newly diagnosed atrial fibrillation were not more likely to undergo anticoagulation, nor were patients treated by internal medicine or cardiology specialists.

CONCLUSIONS

There may be significant warfarin underuse in some hospitals. Overall, approximately one third of patients with atrial fibrillation for whom it appeared appropriate were not anticoagulated with warfarin. Although the fact that data were not available to or were missed by our review surely justifies some of the underuse, one should recall that even a small amount of underuse may affect a large number of people with this common condition.

摘要

背景

多项随机临床试验表明,在房颤患者中,使用华法林钠可预防中风。最近,专家们对执业医师可能未充分使用华法林表示担忧。然而,很少有研究对华法林使用不足的情况进行量化。

方法

我们从宾夕法尼亚州5家小型医院中随机抽取了1993年7月1日至1994年6月30日期间存活出院的65名医疗保险受益人,其出院诊断代码为房颤。经过培训的摘要员核实住院期间曾出现房颤,确定抗凝治疗的禁忌证,并确定每位患者出院时是否使用了华法林或阿司匹林。一名内科医生使用隐含标准来确定在没有华法林明确禁忌证且未接受华法林治疗的患者中不使用华法林的原因。

结果

在审查的322份病历中,48例患者在住院期间未发生房颤,79例有使用华法林的禁忌证,21例死亡或转至其他医院,2例因华法林并发症入院。在其余172例患者中,76例(44%)接受了抗凝治疗。对96例未接受抗凝治疗的患者进行隐含审查后,内科医生判断54例患者不适合使用华法林。排除这些患者后,其余118例患者中有76例(64%)接受了抗凝治疗。未接受华法林治疗的患者年龄稍大(81.6岁对78.3岁),但按医院分层后这一差异无统计学意义。5家医院的华法林使用率差异很大(32%、57%、79%、82%、94%;P<0.001,自由度为4的卡方检验)。新诊断为房颤的患者接受抗凝治疗的可能性并不更高,内科或心脏科专家治疗的患者也是如此。

结论

一些医院可能存在华法林使用严重不足的情况。总体而言,约三分之一似乎适合使用华法林的房颤患者未接受华法林抗凝治疗。尽管我们的审查未能获取或遗漏的数据肯定是导致部分使用不足的原因之一,但应记住,即使少量的使用不足也可能影响大量患有这种常见疾病的人群。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验